- Report
- April 2025
- 200 Pages
Global
From €6977EUR$7,950USD£6,037GBP
- Report
- May 2024
- 132 Pages
Global
From €5704EUR$6,499USD£4,935GBP
- Report
- May 2024
- 134 Pages
Global
From €5704EUR$6,499USD£4,935GBP
Trulance is a type of gastrointestinal drug used to treat chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). It is a guanylate cyclase-C (GC-C) agonist, which works by increasing the secretion of fluid and electrolytes into the intestine, helping to soften stools and increase bowel movements. Trulance is taken orally once daily and is available in tablet form.
Trulance is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2017. It is the first and only GC-C agonist approved for the treatment of CIC and IBS-C in adults. Trulance is a prescription drug and is available in pharmacies across the US.
Some companies in the Trulance market include Synergy Pharmaceuticals, Ironwood Pharmaceuticals, and Allergan. Show Less Read more